
The Parliamentary Standing Committee on Health, in its report titled ‘Vaccine Development, Distribution Management and Mitigation of Pandemic COVID-19’, said…
According to the company, the intranasal vaccine is a heterologous booster dose. Moreover, the vaccine development data will be submitted…
People will no longer be required to wear masks in supermarkets, stores, busses or planes. The last remaining vaccine mandates…
According to experts, Therapeutic Interfering Particle (TIP) is an antiviral procedure that reduces the replication rate and pathogenesis of a…
In the case of Evusheld, the Japanese government has agreed to provide the drug-free of cost to select medical institutions…
On September 6, the Drugs Controller General of India (DCGI) had approved its intranasal Covid vaccine iNCOVACC for restricted emergency…
There were no new deaths, keeping the nation’s death toll at 5,226. As of Saturday, mainland China had confirmed 246,852…
“When we celebrate the achievements of our scientists, science becomes a part of our society, it becomes a part of…
According to the ministry, 214.77 crore vaccine doses have been administered in the country so far under the nationwide COVID-19…
As the world matures into a new era of technological dominance, the generation that came of age with technology finds…
In December last year, this product’s approval in the United States was given by the USFDA and is indicated for…
The team at Tel Aviv University noted that targeted treatment with antibodies and their delivery to the body in high…
In view of the fresh outbreak, Beijing’s health officials asked residents to stay put during the upcoming Mid-Autumn festival holiday…
Artificial intelligence not only helps businesses retain the right talent, but also aids in creating a better digital environment
Considering the fact that Omicron isn’t mild and affects an individual with serious-flu like symptoms, the Omicron-specific vaccine might prove…
The company completed the phase-III and booster dose trials for its intranasal Covid-19 vaccine on August 22.
This vaccine candidate was evaluated in phase I, II and III clinical trials with successful results, a press release from…
Some people with COVID-19 have lingering symptoms for weeks or months after they begin to recover, a condition termed as…